Totally a brilliant chess move made by MNGT to help increase the pressure on Amgn to buy the whole company or watch someone else compete with the HOT,which has an advantage due to it`s almost immediate turnaround time to patient,compared to NEO,and the advanced Hospital facility that`s required for NEO,compared to HOT,also gives HOT the Advantage. Amgn has to be squirming with this move because small cell lung is a big market and there are many potential competitor suitors that would want in,,Merck comes to mind,and BMY too,and many others not yet on our table.
News 
Market Data 
Discover 
